Prediction of binding modes for ligands in the cytochromes P450 and other heme‐containing proteins

The cytochromes P450 (P450s) are a family of heme‐containing monooxygenase enzymes involved in a variety of functions, including the metabolism of endogenous and exogenous substances in the human body. During lead optimization, and in drug development, many potential drug candidates are rejected because of the affinity they display for drug‐metabolising P450s. Recently, crystal structures of human enzymes involved in drug metabolism have been determined, significantly augmenting the prospect of using structure‐based design to modulate the binding and metabolizing properties of compounds against P450 proteins. An important step in the application of structure‐based metabolic optimization is the accurate prediction of docking modes in heme binding proteins. In this paper we assess the performance of the docking program GOLD at predicting the binding mode of 45 heme‐containing complexes. We achieved success rates of 64% and 57% for Chemscore and Goldscore respectively; these success rates are significantly lower than the value of 79% observed with both scoring functions for the full GOLD validation set. Re‐parameterization of metal‐acceptor interactions and lipophilicity of planar nitrogen atoms in the scoring functions resulted in a significant increase in the percentage of successful dockings against the heme binding proteins (Chemscore 73%, Goldscore 65%). The modified scoring functions will be useful in docking applications on P450 enzymes and other heme binding proteins. Proteins 2005. © 2005 Wiley‐Liss, Inc.

[1]  F. Guengerich,et al.  Role of cytochrome P450 enzymes in drug-drug interactions. , 1997, Advances in pharmacology.

[2]  S. Bell,et al.  Crystal Structure of the F87W/Y96F/V247L Mutant of Cytochrome P-450cam with 1,3,5-Trichlorobenzene Bound and Further Protein Engineering for the Oxidation of Pentachlorobenzene and Hexachlorobenzene* 210 , 2002, The Journal of Biological Chemistry.

[3]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[4]  Garrett M Morris,et al.  Conformational changes in nitric oxide synthases induced by chlorzoxazone and nitroindazoles: crystallographic and computational analyses of inhibitor potency. , 2002, Biochemistry.

[5]  R. Raag,et al.  Crystal structures of cytochrome P-450CAM complexed with camphane, thiocamphor, and adamantane: factors controlling P-450 substrate hydroxylation. , 1991, Biochemistry.

[6]  C David Stout,et al.  Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. , 2003, Biochemistry.

[7]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[8]  N. Sigal,et al.  Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Bell,et al.  Molecular recognition in (+)-alpha-pinene oxidation by cytochrome P450cam. , 2002, Journal of the American Chemical Society.

[10]  M C Meyer,et al.  Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. , 1999, Pharmacogenetics.

[11]  T. Poulos,et al.  Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. , 2001, Biochemistry.

[12]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[13]  A J Howard,et al.  Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam. , 1987, Biochemistry.

[14]  T. Poulos,et al.  Crystal Structure of Constitutive Endothelial Nitric Oxide Synthase A Paradigm for Pterin Function Involving a Novel Metal Center , 1998, Cell.

[15]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[16]  J. Tainer,et al.  Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. , 1998, Science.

[17]  R. Raag,et al.  The structural basis for substrate-induced changes in redox potential and spin equilibrium in cytochrome P-450CAM. , 1991, Biochemistry.

[18]  Jeremy R. H. Tame,et al.  Scoring functions: A view from the bench , 1999, J. Comput. Aided Mol. Des..

[19]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[20]  Robin Taylor,et al.  A new test set for validating predictions of protein–ligand interaction , 2002, Proteins.

[21]  T. Poulos,et al.  Implications for Isoform-selective Inhibitor Design Derived from the Binding Mode of Bulky Isothioureas to the Heme Domain of Endothelial Nitric-oxide Synthase* , 2001, The Journal of Biological Chemistry.

[22]  T. Poulos,et al.  CRYSTAL STRUCTURE OF CYTOCHROME P450CAM COMPLEXED WITH ITS CATALYTIC PRODUCT, 5-EXO-HYDROXYCAMPHOR , 1995 .

[23]  Y P Chen,et al.  The Crystal Structure and Amino Acid Sequence of Dehaloperoxidase from Amphitrite ornata Indicate Common Ancestry with Globins* , 2000, The Journal of Biological Chemistry.

[24]  J. Goldstein,et al.  Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. , 2001, Pharmacogenetics.

[25]  S. Moncada,et al.  Inhibition of nitric oxide synthase as a potential therapeutic target. , 1999, Annual review of pharmacology and toxicology.

[26]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[27]  L. Wienkers,et al.  Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[28]  H K Kroemer,et al.  "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. , 1995, Life sciences.

[29]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[30]  M. Eastwood,et al.  Letter: Neutrophil function and myeloperoxidase activity in inflammatory bowel disease. , 1976, Lancet.

[31]  W. Jaeger,et al.  Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.

[32]  S. Takahashi,et al.  Binding of salicylhydroxamic acid and several aromatic donor molecules to Arthromyces ramosus peroxidase, investigated by X-ray crystallography, optical difference spectroscopy, NMR relaxation, molecular dynamics, and kinetics. , 1999, Biochemistry.

[33]  T. Poulos,et al.  Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[35]  M. Eichelbaum,et al.  Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.

[36]  T. Koike,et al.  The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism , 2003, Alimentary pharmacology & therapeutics.

[37]  J. Cupp-Vickery,et al.  Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[39]  J Berendzen,et al.  The catalytic pathway of cytochrome p450cam at atomic resolution. , 2000, Science.

[40]  K. Fukuyama,et al.  Binding mode of benzhydroxamic acid to Arthromyces ramosus peroxidase shown by X‐ray crystallographic analysis of the complex at 1.6 Å resolution , 1997, FEBS letters.

[41]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[42]  T. Poulos,et al.  Crystallographic studies on endothelial nitric oxide synthase complexed with nitric oxide and mechanism-based inhibitors. , 2001, Biochemistry.

[43]  Frank H Allen,et al.  Applications of the Cambridge Structural Database in organic chemistry and crystal chemistry. , 2002, Acta crystallographica. Section B, Structural science.

[44]  Robin Taylor,et al.  New software for searching the Cambridge Structural Database and visualizing crystal structures. , 2002, Acta crystallographica. Section B, Structural science.

[45]  S. Bell,et al.  Molecular Recognition in (+)-a-Pinene Oxidation by Cytochrome P450 cam , 2003 .

[46]  B. K. Vainshtein,et al.  X-Ray Structural Investigation of Leghemoglobin. Vi. Structure of Acetate-Ferrileghemoglobin at a Resolution of 2.0 Angstroms (Russian) , 1983 .

[47]  Gerhard Klebe,et al.  Relibase: design and development of a database for comprehensive analysis of protein-ligand interactions. , 2003, Journal of molecular biology.

[48]  F. Walker,et al.  Ligand-induced heme ruffling and bent no geometry in ultra-high-resolution structures of nitrophorin 4. , 2001, Biochemistry.

[49]  H. Echizen,et al.  Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin , 2003, The Pharmacogenomics Journal.

[50]  D. E. Clark,et al.  Flexible docking using tabu search and an empirical estimate of binding affinity , 1998, Proteins.

[51]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[52]  Irwin D. Kuntz,et al.  Automated flexible ligand docking method and its application for database search , 1997 .

[53]  V. Njar,et al.  Aromatase inhibitors and their application in breast cancer treatment☆ , 2000, Steroids.

[54]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[55]  D. Sohn.  Clinical implications of CYP2C19 polymorphism for tailor-made pharmacotherapy , 2002 .

[56]  T. Poulos,et al.  Mapping the active site polarity in structures of endothelial nitric oxide synthase heme domain complexed with isothioureas. , 2000, Journal of inorganic biochemistry.

[57]  C David Stout,et al.  Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding. , 2003, Biochemistry.

[58]  David S. Goodsell,et al.  Automated docking of ligands to an artificial active site: augmenting crystallographic analysis with computer modeling , 2003, J. Comput. Aided Mol. Des..